Search the Roll Call archive by keyword, date, Congress, section, or tags.
last year stopped approving routine COVID-19 vaccines for the healthy, non-elderly population and consulted in the decision to revamp the Centers for Disease Control and Prevention's childhood vaccine schedule
The company was originally scheduled to produce 62 million vaccines by May, according to the delivery schedule spelled out in Johnson & Johnson’s $1 billion contact with the Biomedical Advanced Research
Energy and Commerce Chairman Frank Pallone Jr. has a bill that would do both, but has yet to schedule a hearing on it.